Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Lymphoma

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 62 articles:
HTML format
Text format



Single Articles


    October 2017
  1. AKHTAR S, Montoto S, Boumendil A, Finel H, et al
    High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European Society for Blood and Marrow Transplantation (EBMT)-Lymphoma Working Party.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24927.
    PubMed     Text format     Abstract available


  2. WILCOX RA
    Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2017;92:1085-1102.
    PubMed     Text format     Abstract available


    September 2017
  3. BELETE H, Burns LJ, Shanley R, Nayar M, et al
    Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients.
    Am J Hematol. 2017;92:E529-E533.
    PubMed     Text format     Abstract available


    August 2017
  4. VOSE JM
    Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Am J Hematol. 2017;92:806-813.
    PubMed     Text format     Abstract available


    July 2017
  5. MALECEK MK, Petrich AM, Rozell S, Chu B, et al
    Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose-Adjusted EPOCH plus Rituximab.
    Am J Hematol. 2017 Jul 18. doi: 10.1002/ajh.24864.
    PubMed     Text format     Abstract available


  6. WITZIG TE, Zinzani PL, Habermann TM, Tuscano JM, et al
    Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma.
    Am J Hematol. 2017 Jul 11. doi: 10.1002/ajh.24854.
    PubMed     Text format     Abstract available


  7. ARMITAGE JO
    The aggressive peripheral T-cell lymphomas: 2017.
    Am J Hematol. 2017;92:706-715.
    PubMed     Text format     Abstract available


    June 2017
  8. JAIN P, Kantarjian H, Jain N, Short NJ, et al
    Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens.
    Am J Hematol. 2017 Jun 24. doi: 10.1002/ajh.24833.
    PubMed     Text format    


  9. WITZIG TE, Johnston PB, LaPlant BR, Kurtin PJ, et al
    Long-term Follow-up of Chemoimmunotherapy with Rituximab, Oxaliplatin, Cytosine Arabinoside, Dexamethasone (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkin Lymphoma: Results of a study of the Mayo Clinic Cancer Research Consortium (MCCRC) MC0
    Am J Hematol. 2017 Jun 14. doi: 10.1002/ajh.24824.
    PubMed     Text format     Abstract available


  10. SAYGIN C, Jia X, Hill B, Dean R, et al
    Impact of Comorbidities on Outcomes of Elderly Patients with Diffuse Large B-cell Lymphoma.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24819.
    PubMed     Text format     Abstract available


  11. LANZA F, Saraceni F, Pezzi A, Martino M, et al
    A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24817.
    PubMed     Text format    


    May 2017
  12. HELBER MJ, Moore JE, Williams AM, Meacham PJ, et al
    Ibrutinib Therapy for Lymphoplasmacytic Lymphoma.
    Am J Hematol. 2017 May 24. doi: 10.1002/ajh.24795.
    PubMed     Text format    


  13. BAIR SM, Strelec L, Nagle SJ, Nasta SD, et al
    Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.
    Am J Hematol. 2017 May 16. doi: 10.1002/ajh.24792.
    PubMed     Text format     Abstract available


    April 2017
  14. BINDER M, O'Byrne MM, Maurer MJ, Ansell S, et al
    Associations between Elevated Pre-treatment Serum Cytokines and Peripheral Blood Cellular Markers of Immunosuppression in Patients with Lymphoma.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24758.
    PubMed     Text format     Abstract available


  15. HANSEN JW, Garde C, Asmar F, Tholstrup D, et al
    Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma.
    Am J Hematol. 2017 Apr 5. doi: 10.1002/ajh.24751.
    PubMed     Text format     Abstract available


    March 2017
  16. MAJOR A, Pan Z, Kamdar M
    Secondary CNS Involvement of ALK-Negative Anaplastic Large Cell Lymphoma.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24733.
    PubMed     Text format    


  17. SHORT NJ, Kantarjian HM, Ko H, Khoury JD, et al
    Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
    Am J Hematol. 2017 Mar 15. doi: 10.1002/ajh.24720.
    PubMed     Text format    


  18. MAURO FR, Galieni P, Tedeschi A, Laurenti L, et al
    Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
    Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24714.
    PubMed     Text format     Abstract available


  19. DURANI U, Go RS
    Incidence, clinical findings, and survival of hepatosplenic T-cell lymphoma in the United States.
    Am J Hematol. 2017 Mar 6. doi: 10.1002/ajh.24711.
    PubMed     Text format    


  20. HUET S, Szafer-Glusman E, Tesson B, Xerri L, et al
    BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.
    Am J Hematol. 2017 Mar 1. doi: 10.1002/ajh.24701.
    PubMed     Text format     Abstract available


    February 2017
  21. ROSENTHAL A, Dueck AC, Ansell S, Gano K, et al
    A Phase 2 study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy.
    Am J Hematol. 2017 Feb 23. doi: 10.1002/ajh.24693.
    PubMed     Text format     Abstract available


  22. KAYA Z, Alici N, Ozmen OE, Akgul M, et al
    Identification of renal infiltration based on urinary findings in a child with burkitt leukemia/lymphoma.
    Am J Hematol. 2017 Feb 22. doi: 10.1002/ajh.24694.
    PubMed     Text format    


  23. BENNANI NN, LaPlant BR, Ansell SM, Habermann TM, et al
    Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
    Am J Hematol. 2017 Feb 17. doi: 10.1002/ajh.24671.
    PubMed     Text format     Abstract available


    January 2017
  24. RIZZO D, Viailly PJ, Mareschal S, Bohers E, et al
    Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas.
    Am J Hematol. 2017;92:68-76.
    PubMed     Text format     Abstract available


    December 2016
  25. GLIMELIUS I, Eloranta S, Ekberg S, Chang ET, et al
    Increased healthcare use up to 10 years among relapse-free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy.
    Am J Hematol. 2016 Dec 22. doi: 10.1002/ajh.24623.
    PubMed     Text format     Abstract available


    November 2016
  26. COSTA LJ, Maddocks K, Epperla N, Reddy NM, et al
    Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Ultra-high Risk Features and Benchmarking for Experimental Therapies.
    Am J Hematol. 2016 Nov 23. doi: 10.1002/ajh.24615.
    PubMed     Text format     Abstract available


  27. BAIN BJ
    Early leukemic transformation of adult T-cell leukemia/lymphoma presenting as meningeal lymphoma.
    Am J Hematol. 2016 Nov 8. doi: 10.1002/ajh.24602.
    PubMed     Text format    


    October 2016
  28. YU H, Sotillo E, Harrington C, Wertheim G, et al
    Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma.
    Am J Hematol. 2016 Oct 25. doi: 10.1002/ajh.24594.
    PubMed     Text format    


  29. ZAJA F, Tabanelli V, Agostinelli C, Calleri A, et al
    CD38, BCL-2, PD-1 and PD-1L expression in nodal peripheral T-cell lymphoma (PTCL): Possible biomarkers for novel targeted therapies?
    Am J Hematol. 2016 Oct 3. doi: 10.1002/ajh.24571.
    PubMed     Text format    


    September 2016
  30. FORDHAM NJ, O'Connor S, Stern S, Nikolova V, et al
    Circulating lymphoma cells in intravascular large B-cell lymphoma.
    Am J Hematol. 2016 Sep 22. doi: 10.1002/ajh.24565.
    PubMed     Text format    


    July 2016
  31. BARRETO JN, Ice LL, Thompson CA, Tosh PK, et al
    Low incidence of Pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving Rituximab-containing combination chemotherapy.
    Am J Hematol. 2016 Jul 29. doi: 10.1002/ajh.24499.
    PubMed     Text format     Abstract available


  32. MAURER MJ, Bachy E, Ghesquieres H, Ansell SM, et al
    Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.
    Am J Hematol. 2016 Jul 27. doi: 10.1002/ajh.24492.
    PubMed     Text format     Abstract available


  33. BLEDSOE JR, Redd RA, Hasserjian RP, Soumerai JD, et al
    The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
    Am J Hematol. 2016 Jul 15. doi: 10.1002/ajh.24485.
    PubMed     Text format     Abstract available


  34. CASTILLO JJ, Gustine J, Meid K, Dubeau T, et al
    Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstrom macroglobulinemia.
    Am J Hematol. 2016 Jul 14. doi: 10.1002/ajh.24477.
    PubMed     Text format     Abstract available


  35. EPPERLA N, Harrington AM, Hemauer K, Shah NN, et al
    Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis.
    Am J Hematol. 2016 Jul 14. doi: 10.1002/ajh.24475.
    PubMed     Text format    


  36. AGBAY RL, Jain N, Loghavi S, Medeiros LJ, et al
    Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Am J Hematol. 2016 Jul 14. doi: 10.1002/ajh.24473.
    PubMed     Text format     Abstract available


  37. PATTISON DA, Hofman MS, Bazargan A, Colman P, et al
    Intense focal pituitary FDG uptake due to Intravascular Large B-Cell Lymphoma in Pyrexia of Unknown Origin.
    Am J Hematol. 2016 Jul 7. doi: 10.1002/ajh.24469.
    PubMed     Text format    


  38. ANTIC D, Milic N, Nikolovski S, Todorovic M, et al
    Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients.
    Am J Hematol. 2016 Jul 6. doi: 10.1002/ajh.24466.
    PubMed     Text format     Abstract available


    June 2016
  39. XIAO DY, Luo S, O'Brian K, Ganti A, et al
    Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
    Am J Hematol. 2016 Jun 30. doi: 10.1002/ajh.24465.
    PubMed     Text format     Abstract available


  40. JARDIN F, Pujals A, Pelletier L, Bohers E, et al
    Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
    Am J Hematol. 2016 Jun 16. doi: 10.1002/ajh.24451.
    PubMed     Text format     Abstract available


  41. ANSELL SM
    Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2016;91:434-42.
    PubMed     Text format     Abstract available


    May 2016
  42. CHEAH CY, Brockelmann PJ, Chihara D, Moskowitz A, et al
    Clinical characteristics and outcomes of patients with hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
    Am J Hematol. 2016 May 24. doi: 10.1002/ajh.24429.
    PubMed     Text format     Abstract available



  43. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients.
    Am J Hematol. 2016;91:E300.
    PubMed     Text format    


  44. CASTILLO JJ, Beltran BE, Miranda RN, Young KH, et al
    EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2016;91:529-37.
    PubMed     Text format     Abstract available


  45. CEPPI F, Weitzman S, Woessmann W, Davies K, et al
    Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
    Am J Hematol. 2016;91:486-91.
    PubMed     Text format     Abstract available


    April 2016
  46. NABHAN C, Zhou X, Day BM, Dawson K, et al
    Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.
    Am J Hematol. 2016 Apr 28. doi: 10.1002/ajh.24401.
    PubMed     Text format     Abstract available


    March 2016
  47. MARINI C, Baldaia H, Trigo F, Castillo JJ, et al
    Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma.
    Am J Hematol. 2016 Mar 25. doi: 10.1002/ajh.24375.
    PubMed     Text format    


  48. GUTIERREZ-CIVICOS R, Hurtado AM, Torres-Moreno D, Sanchez-Blanco JJ, et al
    A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients.
    Am J Hematol. 2016 Mar 7. doi: 10.1002/ajh.24354.
    PubMed     Text format    


  49. ROSENBERG AS, Klein AK, Ruthazer R, Evens AM, et al
    Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder: A Comparative Analysis of Clinical Characteristics, Prognosis, and Survival.
    Am J Hematol. 2016 Mar 1. doi: 10.1002/ajh.24346.
    PubMed     Text format     Abstract available


  50. SUVORAVA N, Richmond S, Patel N, Bell B, et al
    Between a rock and a hard place.
    Am J Hematol. 2016;91:351-3.
    PubMed     Text format    


    February 2016
  51. JACKSON MW, Rusthoven CG, Jones BL, Kamdar M, et al
    Improved Survival with Combined Modality Therapy in the Modern Era for Primary Mediastinal B-Cell Lymphoma.
    Am J Hematol. 2016 Feb 6. doi: 10.1002/ajh.24325.
    PubMed     Text format     Abstract available


  52. PANERO J, Alves-Paiva RM, Roisman A, Santana-Lemos BA, et al
    Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
    Am J Hematol. 2016 Feb 6. doi: 10.1002/ajh.24324.
    PubMed     Text format     Abstract available


  53. GUILLET S, Gerard L, Meignin V, Agbalika F, et al
    Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution.
    Am J Hematol. 2016;91:233-237.
    PubMed     Text format     Abstract available


    January 2016
  54. GHOBRIAL IM, Siegel DS, Vij R, Berdeja JG, et al
    TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom's macroglobulinemia.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24300.
    PubMed     Text format     Abstract available


  55. ALINARI L, Gru A, Quinion C, Huang Y, et al
    De novo CD5+ Diffuse Large B-cell Lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multi-center, rituximab treated cohort.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24299.
    PubMed     Text format     Abstract available


  56. SALE S, Fumi M, Pancione Y, Parente D, et al
    The fortuitous diagnosis of Burkitt lymphoma in a patient with chronic myelomonocytic leukemia.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24297.
    PubMed     Text format    


  57. BACHY E, Estell JA, Van de Neste E, Bouabdallah R, et al
    Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24305.
    PubMed     Text format     Abstract available


    December 2015
  58. FREEDMAN A
    Follicular lymphoma: 2015 update on diagnosis and management.
    Am J Hematol. 2015;90:1171-8.
    PubMed     Text format     Abstract available


    November 2015
  59. WILCOX RA
    Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2015 Nov 26. doi: 10.1002/ajh.24233.
    PubMed     Text format     Abstract available


  60. ADAMS HJ, Kwee TC
    Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?
    Am J Hematol. 2015 Nov 17. doi: 10.1002/ajh.24241.
    PubMed     Text format    


  61. CHRISTOFFER EL-GALALY T, Hutchings M, Villa D
    Reply to H.J Adams et al: "Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?"
    Am J Hematol. 2015 Nov 17. doi: 10.1002/ajh.24239.
    PubMed     Text format    


  62. EL-GALALY TC, Pedersen MB, Hutchings M, Mylam KJ, et al
    Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
    Am J Hematol. 2015;90:975-80.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: